GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Debt-to-Revenue

BetterLife Pharma (XCNQ:BETR) Debt-to-Revenue : N/A (As of Apr. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BetterLife Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was C$0.57 Mil. BetterLife Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2024 was C$1.83 Mil. BetterLife Pharma's annualized Revenue for the quarter that ended in Apr. 2024 was C$0.00 Mil.


BetterLife Pharma Debt-to-Revenue Historical Data

The historical data trend for BetterLife Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Debt-to-Revenue Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

BetterLife Pharma Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of BetterLife Pharma's Debt-to-Revenue

For the Biotechnology subindustry, BetterLife Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Debt-to-Revenue falls into.



BetterLife Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BetterLife Pharma's Debt-to-Revenue for the fiscal year that ended in Jan. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.55 + 0.919) / N/A
=N/A

BetterLife Pharma's annualized Debt-to-Revenue for the quarter that ended in Apr. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.573 + 1.831) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Apr. 2024) Revenue data.


BetterLife Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Ahmad Doroudian Director, Senior Officer